Publications
51
Citations
1,548
Est. group size
~1
Recurring co-author estimate
Active years
27
Publishing since 2000
Allison M. Bradbury's research focuses on developing gene therapies for rare inherited neurological diseases, particularly lysosomal storage disorders like Krabbe disease, mucolipidosis, Sandhoff disease, and vanishing white matter disease. Much of this work uses AAV (adeno-associated virus) and lentiviral vectors to deliver corrective genes to the brain and nervous system, tested in animal models (mouse, cat, dog) as a step toward human clinical treatments. The work also touches on immune responses to gene therapy and combination approaches with stem cell transplantation.
Publication output has fluctuated over the last decade without a clear steady upward or downward trend, with recent years (2023, 2025) showing higher activity compared to a dip in 2024.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Navigating new horizons: Key insights from ASGCT’s 2025 Policy Summit
Molecular Therapy · 2026
- Comparative analysis of cell-specific promoters in AAV9-mediated gene therapy targeting the central nervous system
Molecular Therapy — Methods & Clinical Development · 2025
- Age-sensitive response of systemic AAV-mediated gene therapy in a newly characterized feline model of mucolipidosis II
Molecular Therapy · 2025
- CRISPR-Based Gene Therapy: Implications for the Clinical Laboratory
Clinical Chemistry · 2025
- Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease
Molecular Therapy · 2024
- 400 Investigation of a translational astrocyte-targeted AAV-mediated gene addition therapy in two models of Vanishing White Matter disease
Journal of Clinical and Translational Science · 2024
- AAV-based in vivo gene therapy for neurological disorders
Nature Reviews Drug Discovery · 2023
- Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy
Molecular Therapy · 2023
- CD8+ T cell depletion prevents neuropathology in a mouse model of globoid cell leukodystrophy
The Journal of Experimental Medicine · 2023
- Brain-targeted ex vivo lentiviral gene therapy: Implications for MPS and beyond
Molecular Therapy — Methods & Clinical Development · 2023
- Life‐Limiting Peripheral Organ Dysfunction in Feline Sandhoff Disease Emerges after Effective <scp>CNS</scp> Gene Therapy
Annals of Neurology · 2023
- Editorial: Immunogenicity and toxicity of AAV gene therapy
Frontiers in Immunology · 2023
- Efficacy and Safety of a Krabbe Disease Gene Therapy
Human Gene Therapy · 2022
- Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders
Molecular Therapy · 2022
- Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases
Molecular Therapy · 2022
- Molecular Therapy×8
- Human Gene Therapy×4
- The Neuroradiology Journal×3
- Molecular Therapy — Methods & Clinical Development×2
- Molecular Genetics and Metabolism×2
- Emily de los Reyes
Medicine · The Ohio State University
- Matthew Nichols
Medicine · The Ohio State University
- Molly McPheron
Medicine · Indiana University
- Michael Beck
Medicine · The Ohio State University
- Piotr Hadaczek
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile